BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is associated with an increased risk of thrombosis through unknown mechanisms. DESIGN AND METHODS: We studied 23 patients with PNH, before and after five and 11 weeks of treatment with eculizumab. We examined markers of thrombin generation and reactional fibrinolysis (prothrombin fragment 1+2 (F1+2), D-dimers, and plasmin antiplasmin complexes (P-AP), and endothelial dysfunction tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), soluble thrombomodulin (sTM), intercellular adhesion molecule 1 (sICAM-1), vascular cell adhesion molecule (sVCAM-1), endothelial microparticles (EMPs), and tissue factor pathway inhibitor (TFPI). RESULTS: At baseline, vWF, sVCAM-1, the EMP count, and F1+2 and D-dimer levels were significantly elevated in the patients, including those with no history of clinical thrombosis. Treatment with eculizumab was associated with significant decreases in plasma markers of coagulation activation (F1+2, P=0.012, and D-dimers, P=0.01), and reactional fibrinolysis (P-AP, P=0.0002). Eculizumab treatment also significantly reduced plasma markers of endothelial cell activation (t-PA, P=0.0005, sVCAM-1, P<0.0001, and vWF, P=0.0047) and total (P=0.0008) and free (P=0.0013) TFPI plasma levels. CONCLUSIONS: Our results suggest a new understanding of the contribution of endothelial cell activation to the pathogenesis of thrombosis in PNH. The terminal complement inhibitor, eculizumab, induced a significant and sustained decrease in the activation of both the plasma hemostatic system and the vascular endothelium, likely contributing to the protective effect of eculizumab on thrombosis in this setting.
BACKGROUND:Paroxysmal nocturnal hemoglobinuria (PNH) is associated with an increased risk of thrombosis through unknown mechanisms. DESIGN AND METHODS: We studied 23 patients with PNH, before and after five and 11 weeks of treatment with eculizumab. We examined markers of thrombin generation and reactional fibrinolysis (prothrombin fragment 1+2 (F1+2), D-dimers, and plasmin antiplasmin complexes (P-AP), and endothelial dysfunction tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), soluble thrombomodulin (sTM), intercellular adhesion molecule 1 (sICAM-1), vascular cell adhesion molecule (sVCAM-1), endothelial microparticles (EMPs), and tissue factor pathway inhibitor (TFPI). RESULTS: At baseline, vWF, sVCAM-1, the EMP count, and F1+2 and D-dimer levels were significantly elevated in the patients, including those with no history of clinical thrombosis. Treatment with eculizumab was associated with significant decreases in plasma markers of coagulation activation (F1+2, P=0.012, and D-dimers, P=0.01), and reactional fibrinolysis (P-AP, P=0.0002). Eculizumab treatment also significantly reduced plasma markers of endothelial cell activation (t-PA, P=0.0005, sVCAM-1, P<0.0001, and vWF, P=0.0047) and total (P=0.0008) and free (P=0.0013) TFPI plasma levels. CONCLUSIONS: Our results suggest a new understanding of the contribution of endothelial cell activation to the pathogenesis of thrombosis in PNH. The terminal complement inhibitor, eculizumab, induced a significant and sustained decrease in the activation of both the plasma hemostatic system and the vascular endothelium, likely contributing to the protective effect of eculizumab on thrombosis in this setting.
Authors: Jan Simak; Karel Holada; Antonio M Risitano; Jan H Zivny; Neal S Young; Jaroslav G Vostal Journal: Br J Haematol Date: 2004-06 Impact factor: 6.998
Authors: Ilene C Weitz; Pedram Razavi; Leanne Rochanda; Jeffrey Zwicker; Bruce Furie; David Manly; Nigel Mackman; Ralph Green; Howard A Liebman Journal: Thromb Res Date: 2012-04-28 Impact factor: 3.944
Authors: Vijay V Kakkar; Debra A Hoppenstead; Jawed Fareed; Zbigniew Kadziola; Mike Scully; Roumen Nakov; Hans K Breddin Journal: Blood Date: 2002-03-15 Impact factor: 22.113
Authors: Peter Hillmen; Claire Hall; Judith C W Marsh; Modupe Elebute; Michael P Bombara; Beth E Petro; Matthew J Cullen; Stephen J Richards; Scott A Rollins; Christopher F Mojcik; Russell P Rother Journal: N Engl J Med Date: 2004-02-05 Impact factor: 91.245
Authors: Andreas Schäfer; Frank Wiesmann; Stefan Neubauer; Martin Eigenthaler; Johann Bauersachs; Keith M Channon Journal: Circulation Date: 2004-04-05 Impact factor: 29.690
Authors: Anders Dahm; Astrid Van Hylckama Vlieg; Bjorn Bendz; Frits Rosendaal; Rogier M Bertina; Per Morten Sandset Journal: Blood Date: 2003-01-30 Impact factor: 22.113
Authors: Deniz Goren Sahin; Olga Meltem Akay; Muzaffer Keklik; Vahap Okan; Abdullah Karakus; Cengiz Demir; Mehmet Ali Erkurt; Kadir Ilkkilic; Rahsan Yildirim; Gulsum Akgun Cagliyan; Salih Aksu; Mehmet Hilmi Dogu; Mehmet Sinan Dal; Volkan Karakus; Ali Ihsan Gemici; Hatice Terzi; Engin Kelkitli; Serdar Sivgin; Ali Unal; Mehmet Yilmaz; Orhan Ayyildiz; Serdal Korkmaz; Bulent Eser; Fevzi Altuntas Journal: Ann Hematol Date: 2021-05-14 Impact factor: 3.673
Authors: Hisham A E Awad; Azza A G Tantawy; Rania A El-Farrash; Eman A Ismail; Noha M Youssif Journal: Blood Transfus Date: 2013-11-15 Impact factor: 3.443
Authors: David J Araten; Rosario Notaro; Howard T Thaler; Nancy Kernan; Farid Boulad; Hugo Castro-Malaspina; Trudy Small; Andromachi Scaradavou; Heather Magnan; Susan Prockop; Sara Chaffee; Jason Gonsky; Raymond Thertulien; Roberto Tarquini; Lucio Luzzatto Journal: Haematologica Date: 2011-12-01 Impact factor: 9.941
Authors: Régis Peffault de Latour; Hubert Schrezenmeier; Andrea Bacigalupo; Didier Blaise; Carmino A de Souza; Stephane Vigouroux; Roelf Willemze; Louis Terriou; Andre Tichelli; Mohamad Mohty; Sophie de Guibert; Judith C Marsh; Jakob Passweg; Jean Yves Mary; Gerard Socié Journal: Haematologica Date: 2012-06-11 Impact factor: 9.941